{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:39:43Z","timestamp":1792445983319,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pfizer Health Research Foundation of Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02345-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:43:09Z","timestamp":1784734989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Herpes zoster risk among female survivors of breast cancer in Japan"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4251-0442","authenticated-orcid":false,"given":"Chitose","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2106-0753","authenticated-orcid":false,"given":"Kensuke","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan","family":"Bhaskaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Adomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Y. S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanako","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-0640","authenticated-orcid":false,"given":"Masao","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"3","key":"2345_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10203","key":"2345_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","volume":"394","author":"H Strongman","year":"2019","unstructured":"Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394(10203):1041\u201354.","journal-title":"Lancet"},{"issue":"1","key":"2345_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003504","volume":"18","author":"H Carreira","year":"2021","unstructured":"Carreira H, Williams R, Funston G, Stanway S, Bhaskaran K. Associations between breast cancer survivorship and adverse mental health outcomes: a matched population-based cohort study in the United Kingdom. PLoS Med. 2021;18(1):e1003504.","journal-title":"PLoS Med"},{"key":"2345_CR4","volume":"56","author":"C Kawamura","year":"2025","unstructured":"Kawamura C, Bhaskaran K, Konishi T, Sagara Y, Bando H, Shinozaki T, et al. Non-cancer risks among female breast cancer survivors: a matched cohort study in Japan. Lancet Reg Health West Pac. 2025;56:101519.","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"2345_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3395-z","volume":"18","author":"D Curran","year":"2018","unstructured":"Curran D, Schmidt-Ott R, Schutter U, Simon J, Anastassopoulou A, Matthews S. Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC Infect Dis. 2018;18(1):496.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2345_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40261-017-0581-5","volume":"38","author":"A Mizukami","year":"2018","unstructured":"Mizukami A, Sato K, Adachi K, Matthews S, Holl K, Matsuki T, et al. Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Japanese adults aged 60 years or older: results from a prospective, observational cohort study. Clin Drug Investig. 2018;38(1):29\u201337.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"2345_CR7","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/bjc.2017.124","volume":"116","author":"E Hansson","year":"2017","unstructured":"Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhaskaran K. Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer. 2017;116(12):1643\u201351.","journal-title":"Br J Cancer"},{"issue":"6","key":"2345_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","volume":"39","author":"A Hata","year":"2011","unstructured":"Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537\u201344.","journal-title":"Infection"},{"key":"2345_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0810-6","volume":"15","author":"MA Yenikomshian","year":"2015","unstructured":"Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, et al. The epidemiology of herpes zoster and its complications in Medicare cancer patients. BMC Infect Dis. 2015;15:106.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2345_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","volume":"22","author":"LA Habel","year":"2013","unstructured":"Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82\u201390.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2345_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2911","volume":"348","author":"HJ Forbes","year":"2014","unstructured":"Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:g2911.","journal-title":"BMJ"},{"issue":"6","key":"2345_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020528","volume":"8","author":"EA Yanni","year":"2000","unstructured":"Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000\u20132012. BMJ Open. 2000;8(6):e020528.","journal-title":"BMJ Open"},{"issue":"13","key":"2345_CR13","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1017\/S0950268814003653","volume":"143","author":"B Liu","year":"2015","unstructured":"Liu B, Heywood AE, Reekie J, Banks E, Kaldor JM, McIntyre P, et al. Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. Epidemiol Infect. 2015;143(13):2871\u201381.","journal-title":"Epidemiol Infect"},{"issue":"2","key":"2345_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","volume":"42","author":"SY Chen","year":"2014","unstructured":"Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325\u201334.","journal-title":"Infection"},{"issue":"3","key":"2345_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med. 2021;22(3):118\u201327.","journal-title":"J Gen Fam Med"},{"key":"2345_CR16","unstructured":"ATC\/DDD Index: https:\/\/www.whocc.no\/atc_ddd_index\/ (2025). Accessed 22 Oct 2025."},{"key":"2345_CR17","unstructured":"Anatomical Classification Guidelines V2025 [cited 2025 October 22]. Available from: https:\/\/www.ephmra.org\/sites\/default\/files\/2025-01\/ATC%20Guidelines%202025.pdf."},{"issue":"11","key":"2345_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2022.07.1941","volume":"33","author":"I Vaz-Luis","year":"2022","unstructured":"Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, et al. ESMO expert consensus statements on cancer survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol. 2022;33(11):1119\u201333.","journal-title":"Ann Oncol"},{"key":"2345_CR19","unstructured":"National Cancer Institute. [cited 2026 June 30]. Available from: https:\/\/www.cancer.gov\/about-cancer\/coping\/survivorship."},{"issue":"1","key":"2345_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13555-018-0268-8","volume":"9","author":"S Imafuku","year":"2019","unstructured":"Imafuku S, Matsuki T, Mizukami A, Goto Y, de Souza S, Jegou C, et al. Burden of herpes zoster in the Japanese population with immunocompromised\/chronic disease conditions: results from a cohort study claims database from 2005\u20132014. Dermatol Ther (Heidelb). 2019;9(1):117\u201333.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"2345_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/1346-8138.15214","volume":"47","author":"S Imafuku","year":"2020","unstructured":"Imafuku S, Dormal G, Goto Y, Jegou C, Rosillon D, Matsuki T. Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: results from a claims database cohort study, from 2005 to 2014. J Dermatol. 2020;47(3):236\u201344.","journal-title":"J Dermatol"},{"issue":"3","key":"2345_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s15010-023-02156-y","volume":"52","author":"M Steinmann","year":"2024","unstructured":"Steinmann M, Lampe D, Grosser J, Schmidt J, Hohoff ML, Fischer A, et al. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns. Infection. 2024;52(3):1009\u201326.","journal-title":"Infection"},{"issue":"15","key":"2345_CR23","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/sim.3618","volume":"28","author":"IR White","year":"2009","unstructured":"White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28(15):1982\u201398.","journal-title":"Stat Med"},{"key":"2345_CR24","unstructured":"GlaxoSmithKline KK. Shingrix [package insert; in Japanese]. Tokyo, Japan: GlaxoSmithKline KK. 2024 [cited 2025 Oct 23]. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/ja_JP\/products-info\/shingrix\/shingrix.pdf."},{"issue":"8","key":"2345_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1248\/bpb.b25-00126","volume":"48","author":"A Shono","year":"2025","unstructured":"Shono A, Hoshi SL, Kondo M. Subsidy programs for herpes zoster vaccination in Japanese municipalities. Biol Pharm Bull. 2025;48(8):1185\u201390.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"2345_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1536867X0900900206","volume":"9","author":"PC Lambert","year":"2009","unstructured":"Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265\u201390.","journal-title":"Stata J"},{"key":"2345_CR27","volume-title":"Flexible parametric survival analysis using Stata: beyond the Cox model","author":"P Royston","year":"2011","unstructured":"Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. Stata Press; 2011."},{"issue":"10","key":"2345_CR28","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1002\/pon.3277","volume":"22","author":"YP Hung","year":"2013","unstructured":"Hung YP, Liu CJ, Tsai CF, Hung MH, Tzeng CH, Liu CY, et al. Incidence and risk of mood disorders in patients with breast cancers in Taiwan: a nationwide population-based study. Psychooncology. 2013;22(10):2227\u201334.","journal-title":"Psychooncology"},{"key":"2345_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1667364","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, Tao R, Jiang Y, Ma Z, Xia L. Risk factors for postherpetic neuralgia: a meta-analysis based on demographic, clinical features, and treatment characteristics. Front Immunol. 2025;16:1667364.","journal-title":"Front Immunol"},{"issue":"3","key":"2345_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369(3):255\u201363.","journal-title":"N Engl J Med"},{"issue":"1","key":"2345_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41523-024-00698-4","volume":"10","author":"J Dixon-Douglas","year":"2024","unstructured":"Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen SJ, Savas P, et al. Sustained lymphocyte decreases after treatment for early breast cancer. NPJ Breast Cancer. 2024;10(1):94.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2345_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0669-x","volume":"18","author":"R Verma","year":"2016","unstructured":"Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18(1):10.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2345_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00262-008-0530-5","volume":"58","author":"F Mozaffari","year":"2009","unstructured":"Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Lekander M, Nilsson B, et al. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and\/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunol Immunother. 2009;58(1):111\u201320.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2345_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.clindermatol.2014.04.004","volume":"32","author":"V Ruocco","year":"2014","unstructured":"Ruocco V, Ruocco E, Piccolo V, Brunetti G, Guerrera LP, Wolf R. The immunocompromised district in dermatology: a unifying pathogenic view of the regional immune dysregulation. Clin Dermatol. 2014;32(5):569\u201376.","journal-title":"Clin Dermatol"},{"key":"2345_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcv.2017.11.004","volume":"98","author":"MK Ramirez-Fort","year":"2018","unstructured":"Ramirez-Fort MK, Zeng J, Feily A, Ramirez-Pacheco LA, Jenrette JM, Mayhew DL, et al. Radiotherapy-induced reactivation of neurotrophic human herpes viruses: overview and management. J Clin Virol. 2018;98:18\u201327.","journal-title":"J Clin Virol"},{"issue":"1","key":"2345_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209365","volume":"14","author":"YL Lai","year":"2019","unstructured":"Lai YL, Su YC, Kao CH, Liang JA. Increased risk of varicella-zoster virus infection in patients with breast cancer after adjuvant radiotherapy: a population-based cohort study. PLoS ONE. 2019;14(1):e0209365.","journal-title":"PLoS ONE"},{"issue":"22","key":"2345_CR37","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396.","journal-title":"N Engl J Med"},{"issue":"11","key":"2345_CR38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019\u201332.","journal-title":"N Engl J Med"},{"issue":"6","key":"2345_CR39","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/cid\/ciab125","volume":"73","author":"HS Izurieta","year":"2021","unstructured":"Izurieta HS, Wu X, Forshee R, Lu Y, Sung HM, Agger PE, et al. Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis. 2021;73(6):941\u20138.","journal-title":"Clin Infect Dis"},{"issue":"29","key":"2345_CR40","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1016\/j.vaccine.2021.05.056","volume":"39","author":"Y Sun","year":"2021","unstructured":"Sun Y, Jackson K, Dalmon CA, Shapiro BL, Nie S, Wong C, et al. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39(29):3974\u201382.","journal-title":"Vaccine"},{"issue":"2","key":"2345_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.7326\/M23-2023","volume":"177","author":"O Zerbo","year":"2024","unstructured":"Zerbo O, Bartlett J, Fireman B, Lewis N, Goddard K, Dooling K, et al. Effectiveness of recombinant zoster vaccine against herpes zoster in a real-world setting. Ann Intern Med. 2024;177(2):189\u201395.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2345_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vaccine.2022.10.063","volume":"41","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Farraye FA, Winthrop KL, Willer DO, Vink P, Tavares-Da-Silva F. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. Vaccine. 2023;41(1):36\u201348.","journal-title":"Vaccine"},{"issue":"3","key":"2345_CR43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00103-019-02882-5","volume":"62","author":"A Siedler","year":"2019","unstructured":"Siedler A, Koch J, Garbe E, Hengel H, von Kries R, Ledig T, et al. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2019;62(3):352\u201376.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"2345_CR44","unstructured":"The Australian Technical Advisory Group on Immunisation (ATAGI). Statement on the clinical use of zoster vaccines in adults in Australia. 2022 [cited 2025 Oct 22]. Available from: https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/05\/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia.pdf."},{"key":"2345_CR45","unstructured":"CDC. Clinical Considerations for Shingrix Use in Immunocompromised Adults Aged \u2265\u200919 Years. 2024 [cited 2025 October 22]. Available from: https:\/\/www.cdc.gov\/shingles\/hcp\/vaccine-considerations\/immunocompromised-adults.html."},{"key":"2345_CR46","unstructured":"Food and Drug Administration. Shingrix [package insert], revised: 07\/2025. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. 2025. https:\/\/www.fda.gov\/media\/108597\/download."},{"key":"2345_CR47","unstructured":"Japanese Society for Infection Prevention and Control. Vaccine Guidelines for Healthcare Professionals, 4th ed (in Japanese). [Internet] [cited 2025 Aug 27]. Available from: http:\/\/www.kankyokansen.org\/uploads\/uploads\/files\/jsipc\/vaccine-guideline_04.pdf."},{"key":"2345_CR48","doi-asserted-by":"crossref","unstructured":"Anderson TC, Masters NB, Guo A, LS, Leidner, Lee G, Lee GM, Kotton CN, Dooling KL. Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices\u2014United States. MMWR Morb Mortal Wkly Rep 2022. 2022; 71(3):80\u201384.","DOI":"10.15585\/mmwr.mm7103a2"},{"issue":"3","key":"2345_CR49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17843286.2024.2350258","volume":"79","author":"AF Nikkels","year":"2024","unstructured":"Nikkels AF, Schoevaerdts D, Kauffmann F, Strubbe F, Bensemmane S. Herpes zoster in Belgium: a new solution to an old problem. Acta Clin Belg. 2024;79(3):205\u201316.","journal-title":"Acta Clin Belg"},{"issue":"4","key":"2345_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100548","volume":"7","author":"P Pedrazzoli","year":"2022","unstructured":"Pedrazzoli P, Lasagna A, Cassaniti I, Ferrari A, Bergami F, Silvestris N, et al. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open. 2022;7(4):100548.","journal-title":"ESMO Open"},{"key":"2345_CR51","unstructured":"Japanese Society of Medical Oncology. Medical professionals: Important considerations regarding the initiation of routine herpes zoster vaccination (in Japanese). [Internet]. Tokyo: Japanese Society of Medical Oncology. 2025 Mar 24 [cited 2026 Jul 2]. Available from: https:\/\/www.jsmo.or.jp\/wp\/wp-content\/uploads\/aae12b96a1d3107dcb56b51884e0f197-1.pdf."},{"issue":"2","key":"2345_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcv.2012.06.020","volume":"55","author":"A Lasserre","year":"2012","unstructured":"Lasserre A, Blaizeau F, Gorwood P, Bloch K, Chauvin P, Liard F, et al. Herpes zoster: family history and psychological stress\u2013case\u2013control study. J Clin Virol. 2012;55(2):153\u20137.","journal-title":"J Clin Virol"},{"issue":"1","key":"2345_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","volume":"21","author":"MA Hernan","year":"2010","unstructured":"Hernan MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13\u20135.","journal-title":"Epidemiology"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02345-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02345-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02345-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:01:45Z","timestamp":1792443705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02345-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2345"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02345-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the University of Tsukuba, Ibaraki, Japan (approval number: 1839). The requirement for individual participant consent was waived because the data were anonymized.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KB was funded by a Wellcome Senior Research Fellowship (220283\/Z\/20\/Z). TK received grants from the Kanzawa Medical Research Foundation and Japan Kampo Medicines Manufacturers Association. SY received honoraria from Pfizer, Astra Zeneca, Daiichi Sankyo, Eisai, Eli Lily, Chugai, MSD, Nippon Kayaku, Kyowa Kirin, Sysmex, and Celltrion Healthcare Japan. TS received consultation fees from Takeda Pharmaceutical Co., Ltd. and TMP Medical and lecture fees from Chugai Pharmaceutical Co., Ltd., Novartis, Pfizer Japan, SAS Institute Japan, CMIC HOLDINGS Co., LTD, and Santen Pharmaceutical Co., Ltd. AW received honoraria from Henry Stewart Talk, the 6th annual meeting of the Society for Clinical Epidemiology in Tokyo, and the 28th annual meeting of the Japanese Society for Pharmacoepidemiology. The other authors declare no financial or non-financial competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"179"}}